Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-06-18

FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Aptivus (tipranavir) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aptivus (tipranavir)

Snippet

SUPPL AP for APTIVUS (TIPRANAVIR)